Treatment Paradigms in Advanced Prostate Cancer: Exploring the Role of PARP Inhibitor Combinations

CME: 0.75

Target Audience

This activity is designed to meet the educational needs of medical oncologists, urologic oncologists, nurse practitioners, PAs, nurses and other healthcare professionals who manage patients with mCRPC.

Program Overview

A focused online module that examines the mechanistic rationale, discusses the latest evidence, and explores the potential role of PARP inhibitor-based combination therapy in the treatment of patients with advanced prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the mechanism of action and rationale for combination therapy with PARP inhibitors and AR targeted therapies in the treatment of mCRPC
  • Evaluate clinical evidence on PARP inhibitors in combination with AR targeted therapies for mCRPC
  • Discuss the role of PARP inhibitors in other combination regimens for advanced prostate cancer

Post a comment to this article